ADCendo

Overexpression in tumors due to hypoxia, loss of tumor suppressor genes (such as TP53 and PTEN), and overactivity of MAPK signaling.

Adcendo develops antibody-drug conjugates for solid and mesenchymal cancers, with three programs in clinical trials and others in discovery.

The company aims to provide patients with medicines for underserved cancer indications.

Laura leads Capstan Therapeutics, which develops cell engineering via lipid nanoparticles. She previously served as CEO of Silverback Therapeutics and Synthorx, and holds a B.S. in Microbiology and a Ph.D. in Pharmacology.

Katholieke Universiteit Leuven, Chair of Clinical Advisory Board

Adcendo partners with global healthcare investors to advance cancer therapies and accelerate development of new treatments.

Adcendo ApS is a clinical-stage biotech company headquartered in Copenhagen, Denmark, with operations in Boston, Massachusetts.

To develop breakthrough ADC therapies against hard-to-treat solid tumor & blood cancers

The listed address is c/o Symbion, Frederiksberg Nordre Fasanvej 215, 2000 Frederiksberg, Denmark, and the CVR number is DK38780093.

Adcendo designs antibody-drug conjugates to treat cancers with unmet medical needs.

Adcendo is developing antibody-drug conjugates (ADCs) for cancers with high unmet medical need.

The website collects user interaction data, including IP addresses, device details, and location, to improve functionality and security.

Expanded access allows patients with serious or life-threatening conditions to receive investigational treatments outside clinical trials when alternatives are unavailable.

Adcendo partners with MSD to test its experimental antibody-drug conjugate **ADCE-T02** combined with **KEYTRUDA (pembrolizumab)** in a Phase Ib trial for patients with advanced solid tumors. The collaboration includes a supply agreement to advance the study. Adcendo specializes in developing next-generation antibody-drug conjugates for oncology treatments.

May 2026 · PR NewswireNews article

Adcendo ApS announces clinical and regulatory updates for its pipeline of first- and best-in-class antibody-drug conjugates (ADCs) targeting cancers with high unmet medical needs. The company highlights progress in development for its ADC therapies, aiming to advance treatments in oncology.

Apr 2026 · BioSpaceNews article

Adcendo ApS licenses Multitude Therapeutics’ first-in-class ADC candidate, ADCE-T02, for global commercialization outside Greater China. The deal expands Adcendo’s antibody-drug conjugate (ADC) pipeline through a US$1 billion upfront payment. Multitude retains rights in Greater China and potential milestone payments.

Aug 2024 · European Biotechnology MagazineNews article

Adcendo ApS raises its Series A financing to **82 million EUR** to accelerate development of its first-in-class antibody-drug conjugate (ADC) pipeline. The company specializes in novel ADC therapies targeting unmet needs in oncology. The additional funding supports preclinical and clinical programs for its lead candidates.

Apr 2023 · PR NewswireNews article